VINCENT
VENETOCLAX PLUS AZACITIDINE VERSUS STANDARD INTENSIVE CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND NPM1 MUTATIONS ELIGIBLE FOR INTENSIVE TREATMENT
| Studienleiter | Prof. Dr. Christoph Röllig |
| EudraCT-Nr. | 2021-003248-26 |
| Studientyp | Phase II |
| Indikation | AML |
| ClinicalTrial | NCT05904106 |